Context Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $43.2M
- Price
- $0.4835
- % Change (Daily % change from the live per-ticker quote feed.)
- -6.97%
- Volume
- 2.0M
About
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Quick stats
Shares outstanding91.9M
Computed float69.3M
Float / shares75.4%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001842952
AI Summary
AI-generated1/15
minorneutralearnings
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
Context Therapeutics reported Q2 cash and equivalents of $43.0 million, down from $66.0 million at year-end 2025, with a runway expected to extend into Q4 2027.
R&D expenses increased to $12.5 million, driving a net loss of $14.6 million, which included a $6.5 million charge related to amending the BioAtla license for CT-202.
Pipeline highlights include FDA Fast Track designation for CTIM-76 and interim Phase 1a data, while the company discontinued CT-95 to prioritize resources on CTIM-76 and CT-202.
Red flags
- Cash decreased by $23.0 million in six months
- Net loss widened to $14.6 million from $8.8 million year-over-year
- CT-95 development discontinued